ArticleOncology letters2012
miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status.
Article in Oncology letters, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Increased circulating microRNA-155 as a potential biomarker for breast cancer screening: a meta-analysis.Molecules (Basel, Switzerland) · 2014Pooled it
- The clinicopathological significance of microRNA-155 in breast cancer: a meta-analysis.BioMed research international · 2014Pooled it
- Circulating MicroRNA in Breast Cancer.Cancers · 2026Review
- miRNAs Associated with Axillary Lymph Node Metastasis in Breast Cancer: A Systematic Review and Meta-Analysis.Annals of surgical oncology · 2025Article
- Value of miR-31 and miR-150-3p as diagnostic and prognostic biomarkers for breast cancer.Molecular biology reports · 2024Article
- Effects of HIIT training and HIIT combined with circuit resistance training on measures of physical fitness, miRNA expression, and metabolic risk factors in overweight/obese middle-aged women.BMC sports science, medicine & rehabilitation · 2024Article
- Regulation of the Cell Cycle by ncRNAs Affects the Efficiency of CDK4/6 Inhibition.International journal of molecular sciences · 2023Review
- Breast cancer tumor microenvironment affects Treg/IL-17-producing Treg/Th17 cell axis: Molecular and therapeutic perspectives.Molecular therapy oncolytics · 2023Review
- Non-Coding RNAs Modulating Estrogen Signaling and Response to Endocrine Therapy in Breast Cancer.Cancers · 2023Review
- Dynamic Changes of Circulating Mir-155 Expression and the Potential Application as a Non-Invasive Biomarker in Breast Cancer.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Clinical Evaluation of the Diagnostic Role of MicroRNA-155 in Breast Cancer.International journal of genomics · 2020Article
- Inhibition of breast cancer metastasis by co-transfection of miR-31/193b-mimics.Iranian journal of basic medical sciences · 2018Article
- MicroRNA-378 regulates cell proliferation and migration by repressing RNF31 in pituitary adenoma.Oncology letters · 2018Article
- MicroRNA regulation of progesterone receptor in breast cancer.Oncotarget · 2017Article
- Function and regulation of microRNA-31 in development and disease.Molecular reproduction and development · 2016Review
- MiR-155 expression level changes might be associated with initial phases of breast cancer pathogenesis and lymph-node metastasis.Cancer biomarkers : section A of Disease markers · 2016Article
- MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers?BMC cancer · 2015Article
- Next generation sequencing of pancreatic cyst fluid microRNAs from low grade-benign and high grade-invasive lesions.Cancer letters · 2015Article
- MiRNA-155 mediates TAM resistance by modulating SOCS6-STAT3 signalling pathway in breast cancer.American journal of translational research · 2015Article
- microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity.Molecular cancer · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of the present study was to determine the tissue and plasma levels of microRNA (miR)-155 and miR-31 in 67 patients with invasive intraductal breast cancer and their correlation with the clinicopathological characteristics. Using a quantitative real-time-PCR (qRT-PCR) assay, it was demonstrated that the plasma levels of miR-155 and miR-31 in patients were 6- and 5-fold higher than those in healthy individuals, respectively (P<0.05). In cancerous tissues, miR-155 expression levels were 5-fold higher compared with those in non-cancerous tissues (P<0.05), whereas no difference was observed with miR-31 expression (P>0.05). The expression levels of miR-155, but not miR-31, were inversely correlated with estrogen receptor (ER) and progesterone receptor (PR) expression (ER, r=-0.353, P=0.003; PR, r=-0.357, P=0.003). The tissue and plasma levels of miR-155 and miR-31 were not correlated with epidermal growth factor receptor-2 (HER-2) expression levels. Furthermore, high levels of plasma miR-155 and miR-31 were identified in the tumors of TNM stage II, lymph node metastasis 0-3 and tumor sizes of 2-5 cm in patients who were aged over 52 years. miR-155 was mainly expressed in patients with a pathology score of 3 for ER or PR expression; miR-31 expression was higher in patients with a pathology score of 2. These results suggest that miR-155 and miR-31 are differentially expressed in breast cancer patients. Their correlation with the clinicopathological characteristics may aid the diagnosis and treatment of invasive intraductal breast cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.